Expand AMLX Menu
AMLX MENU

AMLX Latest Press Releases

-- September 9, 2026 --

Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors Business Wire 8:00 AM

-- September 8, 2026 --

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference Business Wire 9:00 AM

-- August 19, 2026 --

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock Business Wire 11:06 PM

-- August 18, 2026 --

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock Business Wire 4:01 PM
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia Business Wire 7:00 AM

-- August 17, 2026 --

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 Business Wire 4:01 PM

-- August 6, 2026 --

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results Business Wire 7:00 AM

-- August 3, 2026 --

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 9:00 AM

-- July 3, 2026 --

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 12:15 PM

-- June 23, 2026 --

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 Business Wire 7:00 AM

-- June 8, 2026 --

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 Business Wire 9:00 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. - AMLX Globe Newswire 8:00 AM

-- May 15, 2026 --

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation Business Wire 12:12 PM

-- May 7, 2026 --

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results Business Wire 7:00 AM

-- May 6, 2026 --

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire 9:00 AM

-- May 5, 2026 --

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia Business Wire 7:00 AM

-- April 30, 2026 --

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 Business Wire 9:00 AM
Market Data Delayed 15 Minutes